VINCENT MED released its interim results, with profit attributable to shareholders of HKD 51.629 million, an increase of 55.1% year-on-year
VINCENT MED released its interim results for the period ending June 30, 2025, with revenue of HKD 449 million, an increase of 18.05% year-on-year; profit attributable to shareholders of HKD 51.629 million, an increase of 55.1% year-on-year; and basic earnings per share of HKD 0.0803. The strong performance in the first half of the year was mainly driven by a 28.6% increase in revenue from imaging disposable products, with gross profit increasing by 33.4% to HKD 159 million and gross margin improving to 35.4%
According to the Zhitong Finance APP, VINCENT MED (01612) released its interim results for the six months ending June 30, 2025, reporting revenue of HKD 449 million, an increase of 18.05% year-on-year; profit attributable to shareholders was HKD 51.629 million, an increase of 55.1% year-on-year; basic earnings per share were HKD 0.0803.
The strong performance in the first half of 2025 was mainly driven by a 28.6% increase in revenue from the imaging disposable products segment.
Revenue from the respiratory products segment rebounded, sufficiently offsetting the decline from the orthopedic support rehabilitation devices segment.
Supported by expanded economies of scale, improved operational efficiency, and reduced inventory provisions, gross profit increased by 33.4% to HKD 159 million. The gross profit margin improved from 31.3% to 35.4%
